Next Level






Gene Silencing


supported by funds from the European Union

copyright microsoft

Would you like to stay updated on news from PRAMO?

    • PRAMOMOLECULAR is developing "self-delivering siRNAs", based on our platform technology, a highly innovative class of drugs that can efficiently down-regulate disease-causing proteins such as mutated or over-expressed proteins


    Pipeline

    Our team

    Merle Fuchs, PhD

    CEO & Co-Founder Tel: +49 171 45 42 042

    fuchs@pramomolecular.com








    Learn more

    Ida Shaef, M.Sc

    CSO & Co-Founder Tel: +49 30 94893350

    shaef@pramomolecular.com








    Learn more

    Thomas Hiller, PhD

    CTO & Co-Founder Tel: +49 30 94893350

    hiller@pramomolecular.com








    Learn more

    Thomas Eichinger, PhD

    Head CMC









    Learn more

    Contact

    We’d love to hear from you. Choose the most convenient method and we’ll get back to you as soon as we can.

    Contact Us

    PRAMOMOLECULAR GmbH


    Robert-Rössle-Strasse 10

    13125 Berlin


    Building D79 / 1st Floor


    +49 30 94893350

    Investment Information Sheet (IIS) in accordance with Sections 2a and 13 of the German Investment Products Act (VermAnlG) of PRAMOMOLECULAR GmbH


    This document is an English translation of the original German version of the Vermögensanlagen-Informationsblatt (VIB). It is provided for informational purposes only and has no legal or official meaning. In case of any discrepancies or legal relevance, only the German version shall be binding.

    PRAMOMOLECULAR  supported by